Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
Launched by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER · Mar 25, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a single dose of ketamine given during surgery can help patients with serious orthopedic injuries manage their pain better, reduce their need for opioid medications, and improve their mental health after surgery. The researchers will compare patients who receive ketamine to those who get standard anesthesia (the usual medicine used to keep patients comfortable during surgery). They want to find out if the patients who receive ketamine experience less pain, need fewer opioids, and show improvements in symptoms of depression and post-traumatic stress disorder (PTSD).
To participate in this study, you need to be an adult between 18 and 65 years old, undergoing surgery for a serious bone or joint injury. You should be able to provide consent (or have someone authorized to give consent for you). If you join the study, you'll either receive ketamine or the standard anesthesia during your surgery. Afterward, you’ll fill out surveys about your pain levels, depression, and PTSD symptoms at different times over the next six months. The research team will stay in touch with you through clinic visits and phone calls to check on your progress. This trial is not yet recruiting participants, but it aims to provide valuable information on managing pain and mental health in patients recovering from serious injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-65
- • Undergoing acute operative fixation for musculoskeletal trauma
- • Injury Severity Score (ISS) greater than 15
- • Ability to provide informed consent (or consent provided by a legally authorized representative)
- Exclusion Criteria:
- • Age under 18 or over 65
- • Use of ketamine for preoperative or postoperative sedation
- • Known allergy or contraindication to ketamine
- • Prior unsuccessful ketamine therapy for major depressive disorder (MDD) or PTSD
- • Severe psychiatric conditions or psychotic features
- • History of dementia or glaucoma
- • Currently engaged in trauma-focused cognitive behavioral therapy or PTSD psychotherapy started within the past 3 months
About Texas Tech University Health Sciences Center
Texas Tech University Health Sciences Center (TTUHSC) is a prominent academic institution dedicated to improving health outcomes through innovative research, education, and clinical practice. As a leading sponsor of clinical trials, TTUHSC leverages its interdisciplinary expertise to advance medical knowledge and patient care. The institution is committed to conducting rigorous, ethically sound research that adheres to the highest standards of scientific integrity. With a focus on diverse health issues, TTUHSC fosters collaboration among healthcare professionals, researchers, and community stakeholders to translate research findings into effective treatments and interventions for the benefit of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lubbock, Texas, United States
Lubbock, Texas, United States
Patients applied
Trial Officials
Max E. Davis Assistant Professor, MD
Principal Investigator
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery,
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported